Spruce Biosciences, Inc. Common Stock Asset Resilience Ratio
Spruce Biosciences, Inc. Common Stock asset resilience ratio. Spruce Biosciences, Inc. Common Stock (SPRB) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Spruce Biosciences, Inc. Common Stock (SPRB) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Spruce Biosciences, Inc. Common Stock (2020–2023)
Asset resilience ratio of Spruce Biosciences, Inc. Common Stock from 2020 to 2023. This chart shows how Spruce Biosciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read how much debt does Spruce Biosciences, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Spruce Biosciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SPRB total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Spruce Biosciences, Inc. Common Stock maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Spruce Biosciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Spruce Biosciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Spruce Biosciences, Inc. Common Stock Asset Resilience Ratio by Year (2020–2023)
Spruce Biosciences, Inc. Common Stock asset resilience ratio by year from 2020 to 2023. The table below shows the annual Asset Resilience Ratio data for Spruce Biosciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $103.95 Million | -- |
| 2022-12-31 | 63.74% | $54.59 Million | $85.65 Million | +27.20pp |
| 2021-12-31 | 36.54% | $46.22 Million | $126.49 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $162.88 Million | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more